Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: DMS

Market Cap 33.43M 38.79M 30.78M 28.9M 54.27M 3.67B 54.84M 364M 142M 1.8B 146M 142M 6.22B P/E Ratio 2026 *
43x
P/E Ratio 2027 * 12.9x
Enterprise Value 48.83M 56.66M 44.97M 42.22M 79.27M 5.36B 80.1M 531M 207M 2.62B 213M 208M 9.09B EV / Sales 2026 *
0.86x
EV / Sales 2027 * 0.63x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 39.09M
-2.00%-3.23%-14.29%-19.80% 13.72B
+0.69%-1.06%+84.20%+14.73% 5.07B
-1.62%+0.41%-40.01%-65.34% 1.25B
-2.27%-3.49%-33.37%-43.58% 1.23B
-0.58%-6.14%+54.64%+78.81% 1.16B
-1.23%+1.53%-41.67% - 978M
+5.92%+4.42%+211.61%+211.77% 720M
-6.64%-9.95% - - 361M
-3.14%+7.27%-59.37%+187.67% 245M
Average -1.09%+2.29%+20.22%+52.04% 2.75B
Weighted average by Cap. -1.19%+0.50%+12.31%-1.83%

Financials

2026 *2027 *
Net sales 56.8M 65.91M 52.3M 49.11M 92.2M 6.23B 93.17M 618M 241M 3.05B 247M 242M 10.58B 65.9M 76.47M 60.68M 56.98M 107M 7.23B 108M 717M 279M 3.54B 287M 281M 12.27B
Net income 800K 928K 737K 692K 1.3M 87.77M 1.31M 8.7M 3.39M 42.98M 3.48M 3.41M 149M 2.6M 3.02M 2.39M 2.25M 4.22M 285M 4.27M 28.29M 11.02M 140M 11.32M 11.08M 484M
Net Debt 15.4M 17.87M 14.18M 13.31M 25M 1.69B 25.26M 168M 65.28M 827M 67.06M 65.64M 2.87B 8M 9.28M 7.37M 6.92M 12.99M 878M 13.12M 87.05M 33.91M 430M 34.84M 34.1M 1.49B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!